GOAI Stock: EVA Live’s Going-Concern Risk

On August 3, 2026, EVA Live, Inc. (NASDAQ: GOAI) filed a quarterly report that told shareholders the company might not survive the next twelve months. The filing, a 10-Q covering the period ended June 30, contains explicit going-concern language: substantial doubt about the company’s ability to continue operating.

Start with how fast the money goes. Operating activities consumed $5.2 million in the first half of 2026, which works out to roughly $870,000 of cash burned every month. EVA Live finished June with $2.2 million in the bank, and the same six months produced a $10.3 million net loss.

The counterweight is a single line item: $15.4 million of accounts receivable, about seven times cash on hand, per the 10-Q summary filed August 3, 2026. Solvency for this company now depends on collecting that book, not on shipping a new product or landing a second analyst.

Key Takeaways

EVA Live reported a $10.3 million net loss for the first half of 2026 on $5.2 million of operating cash burn, with $2.2 million of cash at June 30, 2026.
Q2 2026 revenue was $4.2 million, up 1.59% from $4.1 million a year earlier, while the quarter swung to a $1.75 million net loss from net income of $2.63 million in the prior-year period.
The company began trading on Nasdaq on January 28, 2026 under the ticker GOAI after leaving the OTCQB.
Maxim Group initiated coverage on October 13, 2026 with a Buy rating and a $7.00 price target, the only published sell-side target on the name.
Two securities law firms disclosed board investigations, one on October 9 and one on October 13, 2026.

What EVA Live Sells, and What It Has Actually Earned

EVA Live describes itself as an artificial intelligence and autonomous technology company that develops and commercializes AI-powered products, according to its own corporate releases. Its newest named offering is EvaFarmSight, an AI-driven precision agriculture platform announced October 29, 2026. The launch announcement attached the product to a precision agriculture market it said is projected to reach $38.8 billion. That is a market-size projection tied to a launch announcement, and no revenue contribution from EvaFarmSight has been disclosed.

AI precision agriculture drone flying over farmland — EvaFarmSight attaches the company to a precision agriculture market projected at $38.8 billion. No revenue from the platform has been reported.

The revenue that exists today comes from the legacy operating business. Trailing twelve-month revenue through June 30, 2026 was $17.32 million, and fiscal 2025 revenue was $17.04 million, up 82.59% from the prior fiscal year, according to Stock Analysis. That 2025 growth rate is the strongest number in the company’s record, and it is also why the 2026 flattening stands out.

The Q2 2026 Filing: Growth Stalled, Losses Did Not

Revenue for the quarter ended June 30, 2026 was $4.2 million, a slight increase from $4.1 million in the same period of 2025, per AssetRoom’s read of the filing. That is a gain of 1.59%. Sequentially the quarter improved 7.7% from the first quarter, according to WallStreetZen. After a year of 82.59% annual growth, low single-digit year-over-year expansion is the most important change in the business.

Quarterly financial report showing revenue and loss charts — Q2 2026 revenue grew 1.59% year over year while the quarter swung from net income of $2.63 million to a net loss of $1.75 million.

Profitability went the other way. EVA Live posted a net loss of roughly $1.75 million for Q2 2026, or $0.05 per share, against net income of $2.63 million in the prior-year quarter, per Trefis. Q2’s loss covers only part of the $10.3 million first-half total, which implies the first quarter absorbed most of the damage.

Data vendors do not agree on the growth rate, and the gap matters. One screener lists Q2 2026 revenue as up 114.20% year over year, per Tickergate, while the $4.2 million against $4.1 million comparison in the filing supports 1.59%. Investors comparing GOAI across screeners should treat the 10-Q as the authority and discount the higher figure.

Nasdaq Uplisting, Insider Buying, and One Analyst Target

EVA Live was approved for listing on the Nasdaq Stock Market and began trading there on January 28, 2026 under its existing symbol, GOAI, after previously trading on the OTCQB. The company announced the approval in a January 27, 2026 release. The move gave existing holders a liquid national exchange venue in place of the OTC market, a change that matters for institutions barred from buying bulletin-board names.

Chief executive David Boulette has been buying in the open market. A September 29, 2026 disclosure described a second recently reported open-market purchase and put his direct ownership above 23.2 million shares, according to a company announcement. Buying with personal money is a real signal, and it does not close the cash shortfall.

On October 13, 2026, Maxim Group initiated research coverage with a Buy rating and a $7.00 price target, per the announcement. One initiation is not a consensus, and a single target on a company this size carries less weight than a range of estimates. The valuation behind it assumes receivables convert to cash and EvaFarmSight becomes a revenue line. Neither has happened yet.

Two Securities Investigations Into the Board

The Law Offices of Howard G. Smith announced on October 9, 2026 that it is investigating potential claims against EVA Live’s board of directors over whether the board breached its fiduciary duties to shareholders, according to the firm’s release. The Law Offices of Frank R. Cruz disclosed a parallel investigation on October 13, 2026, per Business Wire.

Both are investigations, not filed complaints, and neither firm has stated a specific dollar claim. Shareholder probes of this type often end without litigation. They still add legal cost and management distraction to a company already reporting going-concern doubt, and they tend to appear after a stretch of sharp share price deterioration, which is notable when the firms say nothing about the underlying numbers.

The Balance Sheet Items That Decide the Next Two Quarters

Three items outweigh everything else in the Q2 filing. First, $15.4 million of accounts receivable against $2.2 million of cash. The company’s own going-concern language ties survival to collecting that book, and aged receivables that do not convert turn into write-downs that deepen the loss in the quarter they are recognized.

Second, a $6.5 million convertible note held by Streeterville. Convertible debt closed an immediate funding gap while transferring value to noteholders if the stock is weak at conversion. The share issuance that follows dilutes everyone, including the 23.2 million shares Boulette now holds directly.

Third, the pace of disclosure. EVA Live’s 2026 filing stream has run heavy, mixing financing notices, product releases, the Nasdaq listing, and quarterly results. Each 8-K can reprice the equity, and tracking a story that moves this often raises the cost of holding it.

Every Figure Used Here, in One Place

Metric	Figure	Period or as-of date
Revenue, Q2 2026	$4.2 million	Quarter ended June 30, 2026
Revenue, Q2 2025	$4.1 million	Quarter ended June 30, 2025
Net loss, Q2 2026	$1.75 million ($0.05 per share)	Quarter ended June 30, 2026
Net income, Q2 2025	$2.63 million	Quarter ended June 30, 2025
Net loss, first half 2026	$10.3 million	Six months ended June 30, 2026
Operating cash used, first half 2026	$5.2 million	Six months ended June 30, 2026
Cash and equivalents	$2.2 million	June 30, 2026
Accounts receivable	$15.4 million	June 30, 2026
Streeterville convertible note	$6.5 million	Q2 2026 10-Q
Revenue, trailing twelve months	$17.32 million	Through June 30, 2026
Revenue, fiscal 2025	$17.04 million	Fiscal year 2025
Net loss, fiscal 2025	$8.1 million	Fiscal year 2025
Maxim Group price target	$7.00, Buy rating	October 13, 2026
CEO David Boulette direct ownership	Above 23.2 million shares	September 29, 2026

What to Watch in the Next Reporting Cycle

The next hard data point is the Q3 2026 10-Q. It will show whether the $15.4 million receivable balance fell and whether cash climbed above $2.2 million without new financing. A decline in receivables alongside stable revenue would support the argument that the loss is a timing problem. A flat receivable balance paired with a fresh note would not.

Collections: any disclosure showing receivables converting to cash, or an allowance taken against them.
EvaFarmSight revenue: the first quarter the precision agriculture platform contributes a reported figure instead of a market-size projection.
Dilution: share count changes tied to the Streeterville note and any subsequent financing.
Legal status: whether either investigation becomes a filed complaint with a stated claim.
Coverage breadth: whether a second brokerage initiates, turning the lone $7.00 target into a consensus.

EVA Live now trades on a national exchange with a named product pipeline and a chief executive buying his own stock. It also carries a going-concern disclosure, convertible debt, and two board investigations. The Q2 2026 filing resolves none of that tension. The Q3 numbers and the receivable balance will.

More in-depth coverage from this blog on closely related topics:

Sources and References

Sources cited while researching and writing this article: